Abstract: The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these.

Abstract: The present invention relates to provision of a pharmaceutical agent useful for the prevention and treatment of hepatocellular carcinoma, and the pharmaceutical agent for the prevention and/or treatment of hepatocellular carcinoma contains an acyclic retinoid, a salt thereof, or a solvate of any of these, in combination with a branched-chain amino acid, a salt thereof, or a solvate of any of these.

Abstract: An inhibitor against TGF-? expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant alteration of carcinoma in a liver.

Abstract: An inhibitor against TGF-? expression and an inhibitor against transformation of a hepatitis and/or cirrhosis cell which comprise as an active ingredient a polyprenyl compound such as a polyprenyl carboxylic acid (for example, 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid). The inhibitor can be used as an inhibitor against onset, recurrence (second oncogenesis), and malignant alteration of carcinoma in a liver.

Abstract: A triazolo-1,4-diazepine compound having the formula (I): wherein A represents CO, CO—B, or B, B represents a C1 to C6 alkylene group or a C2 to C6 alkylene group having an oxygen atom interposed in the middle thereof, X represents N—O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1 to C6 lower alkyloxy group or a C1 to C6 lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1 represents a hydrogen atom or a C1 to C3 lower alkyl group having both a PAF antagonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.

Abstract: A 1,4-dihydropyridine compound having the formula (I): ##STR1## wherein, R.sup.1 indicates --COO--A--(3-pyridyl), A indicates a C.sub.3 -C.sub.6 straight chain alkylene group in which one piperazine may be interposed; R.sup.2 indicates a C.sub.2 -C.sub.10 alkyl group, alkenyl group or alkynyl group; a lower alkyl group or lower alkenyl group having a substituent; or a cycloalkyl group which may have a substituent; R.sup.3 indicates the same group as R.sup.1 or --COO--R.sup.4 ; and R.sup.4 indicates a lower alkyl group which may have a substituent or its pharmacologically acceptable salt and an anti-allergenic drug, antiphlogistic, drug for overcoming resistance to anti-cancer drugs, or drug for reinforcing the effect of anti-cancer drugs containing the same as effective ingredients.

Abstract: A 1,4-dihydropyridine derivative having the formula (I): ##STR1## wherein R.sub.1 represents 2-(5,6-dihydro-p-dioxinyl) group, R.sub.2 represents a pyridyl group which may be substituted with one methyl group or ethyl group, and n is an integer of 1 to 4.